Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 13, Issue 2, 2010, Pages 229-241

  Lydiard, R Bruce ^a   Rickels, Karl ^b   Herman, Barry ^c   Feltner, Douglas E ^c  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

Author keywords

Generalized anxiety disorder; Pregabalin (PGB); Psychic anxiety; Somatic anxiety

Indexed keywords

ALPRAZOLAM; LORAZEPAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEAR; FEMALE; GASTROINTESTINAL TRACT; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; INTELLIGENCE; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; MUSCLE; PRIORITY JOURNAL; PSYCHIC ANXIETY FACTOR; RESPIRATORY SYSTEM; SOMATIC ANXIETY FACTOR; SOMATOSENSORY SYSTEM; UROGENITAL SYSTEM;

ADOLESCENT; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77949654119     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990460     Document Type: Article

References (40)

1. APA (1980). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
2. APA (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd revised edn. Washington, DC: American Psychiatric Association.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
4. Brawman-Mintzer O, Lydiard RB, Crawford MM, Emmanuel N, et al. (1994). Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. American Journal of Psychiatry 151, 930-932.
5. Dahl AA, Ravindran A, Allgulander C, Fayaad R, Austin C (2003). Efficacy of sertraline in acute treatment of generalized anxiety disorder (GAD): item and factor analysis. Paper presented at the 2003 Meeting of the American Psychiatric Association.
6. Dooley DJ, Donovan CM, Pugsley TA (2000a). Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. Journal of Pharmacology and Experimental Therapeutics 295, 1086-1093.
7. Dooley DJ, Mieske CA, Borosky SA (2000b). Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neuroscience Letters 280, 107-110.
8. Fehrenbacher JC, Taylor CP, Vasko MR (2003). Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133-144.
9. Feighner JP, Cohn JB (1989). Analysis of individual symptoms in generalized anxiety-a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21, 124-130.
10. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, et al. (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240-249.
11. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236.
12. Gee NS, Brown JP, Dissanayake VU, Offord J, et al. (1996). The novel anticonvulsant drug, gabapentin (neurontin), binds to the alpha2delta subunit of a calcium channel. Journal of Biological Chemistry 271, 5768-5776.
13. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 5055.
14. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
15. Kasper S, Herman B, Nivoli G, van Ameringen M, et al. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology 24, 87-96.
16. Katz IR, Reynolds CF, Alexopoulos GS, Hackett D (2002). Venlafaxine ER as a treatment for generalized anxiety disorders in older adults: pooled analysis of five randomized placebo-controlled trials. Journal of the American Geriatric Society 50, 18-25.
17. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 617-627.
18. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry 156, 1915-1923.
19. Lipman R, Covi L (1976). Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R, Klein DL (Eds), Evaluation of the Psychological Therapies. Baltimore: Johns Hopkins University Press.
20. 3H]glutamate from rat caudal trigeminal nucleus slices. Pain 93, 191-196.
21. Meoni P, Hackett D, Lader M (2004). Pooled analysis of venlafaxine XR efficacy on psychic and somatic symptoms of anxiety in patients with generalized anxiety disorder. Depression and Anxiety 19, 127-132.
22. Meoni P, Salinas E, Brault Y, Hackett D (2001). Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 62, 888-893.
23. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67, 771-782.
24. Pande AC, Crockatt JG, Feltner DE, Janney CA, et al. (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. American Journal of Psychiatry 23, 240-249.
25. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25, 151-158.
26. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, et al. (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350-357.
27. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behaviour and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Diseases 148, 87-98.
28. Rhudy JL, Meagher MW (2000). Fear and anxiety: divergent effects on human pain thresholds. Pain 84, 65-75.
29. Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50, 884-895.
30. Rickels K, Pollack MH, Feltner DE, Lydiard RB, et al. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 1022-1030.
31. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968-974.
32. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H (1988). Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Archives of General Psychiatry 45, 444-450.
33. Rickels K, Weisman K, Norstad N, Singer M, et al. (1982). Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical Psychiatry 43, 81-86.
34. Rickels K, Zaninelli R, McCafferty J, Bellew K, et al. (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749-756.
35. Robinson DS, Khan A (2004). Dosing strategies for antidepressant clinical trials: a commentary. Journal of Clinical Psychopharmacology 24, 1-3.
36. Roy-Byrne PP (1996). Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Journal of Clinical Psychiatry 57 (Suppl. 7), 86-91.
37. Stahl SM, Ahmed S, Haudiquet V (2007). Analysis of the rate of improvement of specific psychic and somatic symptoms of generalized anxiety disorder during long-term treatment with venlafaxine-ER. CNS Spectrums 12, 703-711.
38. Taylor CP, Vartanian MG, Yuen PW, Bigge C, et al. (1993). Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Research 14, 11-15.
39. Wittchen HU, Kessler RC, Beesdo K, Krause P, et al. (2002). Generalized anxiety and depression in primary care: prevalence, recognition, and management. Journal of Clinical Psychiatry 63 (Suppl. 8), 24-34.
40. Yonkers KA, Bruce SE, Dyck IR, Keller MB 2003 Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depression and Anxiety 17, 173-179.